Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
07 Septembre 2023 - 3:00PM
Business Wire
– Recipients include 20 individuals living with Duchenne
muscular dystrophy and five siblings of individuals living with
Duchenne
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, today announced 25
recipients of Route 79, The Duchenne Scholarship Program for the
2023-2024 academic year. Of the 25 recipients, academic
scholarships will be awarded to 20 individuals living with Duchenne
muscular dystrophy and to five siblings of individuals living with
Duchenne. Each recipient will receive a scholarship of up to
$5,000.
“On behalf of Sarepta and the selection committee, we are proud
to announce the recipients of Route 79, The Duchenne Scholarship
Program, for the 2023-2024 academic year. We continue to be
impressed by each applicant and this year, we selected a total of
25 exceptionally bright students with passion for growth and a
strong vision for their future,” said Diane Berry, Sarepta’s
Executive Vice President and Chief Global Policy & Advocacy
Officer. “Each student’s essay demonstrated enthusiasm for their
academic and life goals, a keen curiosity and admirable desire to
learn, and the power of their own perseverance. We are honored to
support this ambitious group of students and we wish them great
success in their studies for the school year ahead.”
The Route 79 program was created in 2018 to recognize
exceptional individuals living with Duchenne as they pursue their
post-secondary education. In 2022, Sarepta expanded the program to
include siblings of individuals with Duchenne in recognition of the
impact that a diagnosis of Duchenne may have on the entire family.
Recipients of the scholarship are chosen by an independent
selection committee composed of Duchenne community members, who
consider each applicant’s community involvement and personal essay.
In addition to application review by the independent committee,
submissions are de-identified for the voting panel with no
indication of whether the candidate has received, or plans to
receive, a Sarepta therapy.
2023-2024 Route 79 Scholarship Recipients
- John "Jack" Becker, Embry-Riddle Aeronautical University,
Daytona Beach
- Christopher Cameron, Ball State University
- Jacob Colby, The Evergreen State College
- Kyle Cox, Texas A&M University
- Agranil Das, Stony Brook University
- Blake Deakin, Arizona State University
- Corbin Fanning, Texas A&M University
- Aiden Fecteau, Eastern Connecticut State University
- Yuvaraj Gambhir, University of Pennsylvania
- Declan Hickey, Curry College
- Yujia Ji, The Ohio State University
- Elliott Johnson, Lebanon Valley College
- Ryan Lugo, State University of New York at New Paltz
- Brian Madura, New Jersey Institute of Technology
- Josh Pflueger, Texas Christian University
- Jasdeep Singh, Cleveland Institute of Art
- Vedant Singhania, San Jose State University
- Connor Underwood, Pikes Peak State College
- Braden Van Eperen, Union College
- Jack Wolf, University of Akron
2023-2024 Route 79 Sibling Scholarship Recipients
- Hailey Baquiran, Dominican University of California
- Ellyn Beebe, University of Tennessee at Martin
- Isabel Dreher, University of New Hampshire
- Lance Hains, West Chester University
- Grace Lee, University of Colorado Boulder
About Route 79, The Duchenne Scholarship Program
The Route 79 program is designed to help students living with
Duchenne and siblings of individuals living with Duchenne pursue
their post-secondary educational goals. Scholarship recipients are
chosen by an independent committee of Duchenne community members
based on an applicant’s community involvement, personal essay, and
recommendation letter. The underlying cause of Duchenne is a
difference in the gene coding for dystrophin. Dystrophin is an
essential protein that plays a pivotal role in muscle structure,
function and preservation. The numerical significance of the
scholarship’s name, Route 79, ties to the 79 exons of the
dystrophin gene. For more information, visit
sarepta.com/route79.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic
medicine for rare diseases that devastate lives and cut futures
short. We hold leadership positions in Duchenne muscular dystrophy
(DMD) and limb-girdle muscular dystrophies (LGMDs), and we
currently have more than 40 programs in various stages of
development. Our vast pipeline is driven by our multi-platform
Precision Genetic Medicine Engine in gene therapy, RNA and gene
editing. For more information, please visit www.sarepta.com or
follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors
in the 'For Investors' section of our website at www.sarepta.com.
We encourage investors and potential investors to consult our
website regularly for important information about us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230907578056/en/
Investor: Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media: Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Sierra Smith, 617-710-1385 sismith@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024